Changes to the Board of Directors

At the forthcoming Annual Shareholders’ Meeting, the Board of Directors will propose the re-election of Mr. Henrik Gürtler as Chairman and the election of Mr. Jørgen Buhl Rasmussen as the new Vice Chairman. The Board of Directors is recommending Mr. Rasmussen as Vice Chairman to further benefit from his experience of running global businesses with significant positions in emerging markets. Mr. Rasmussen has been a member of Novozymes’ Board of Directors since 2011.  

To allow for Mr. Rasmussen to take up the position as Vice Chairman, Ms. Agnete Raaschou-Nielsen will step down as Vice Chairman. The Board of Directors proposes the election of Ms. Raaschou-Nielsen as a member of the Board.

The Board of Directors will further propose the re-election of Dr. Heinz-Jürgen Bertram, Mr. Lars Green and Professor Mathias Uhlén, and the election of Mr. Eivind Kolding as a new member. Ms. Lena Olving is not seeking re-election to the Board of Directors.

Mr. Eivind Kolding, born in 1959, currently serves as CEO of Novo A/S and as a member of the board of directors of Novo Nordisk A/S, NNIT A/S and the Sonion Group. Mr. Kolding has completed the AMP at Wharton Business School in the U.S. and holds a Master of Law degree from the University of Copenhagen, Denmark. The Board of Directors recommends the election of Mr. Kolding based on his extensive leadership experience in large international companies headquartered in Denmark, significant economic insight, and experience of foundation-owned companies and board work.